ADVA
30.6.2022 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today achieved an industry first with the introduction of its Oscilloquartz high-performance optical cesium atomic clock. The coreSync™ OSA 3300-HP is ADVA’s latest innovation in assured PNT, ushering in a new age of precise synchronization with unprecedented stability. Following ADVA’s launch of the first optical pumping timing solution two years ago, the OSA 3350 ePRC+, the OSA 3300-HP takes the technology to new levels. It has a 10-year lifetime compared to the five years offered by currently available high-performance magnetic clocks. As the market’s only high-performance optical cesium clock, the OSA 3300-HP sets a new benchmark for precision and availability, providing the resilience required for PNT assurance in critical infrastructure and empowering service providers to deliver differentiated SLA timing offerings with integrated GNSS backup. The feature-rich device has embedded Ethernet- and IP-based management as well as a user-friendly touchscreen GUI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005667/en/
“The launch of our coreSync™ OSA 3300-HP marks a key milestone in the design of atomic frequency and phase standards. After many years of extensive work in our Swiss laboratories supported by the European Space Agency, we now have a mature, state-of-the-art technology that enables a major leap in the accuracy and stability of network timing while providing a substantially longer lifetime,” said Gil Biran, GM of Oscilloquartz, ADVA. ”From 5G mobile services to mission-critical defense applications, our OSA 3300-HP will be a truly disruptive enhancement of our aPNT+™ technology. And what makes its arrival so significant is that it comes at a moment when existing synchronization solutions in fixed, wireless and cable networks are being stretched to the limit, while the threat of GNSS cyberattacks also continues to grow. Across a wide range of industries, our high-performance cesium atomic clock will meet new timing demands, create new value and open up new possibilities for PNT assurance in critical infrastructure.”
Atomic clocks offer the ultimate synchronization backup for networks that rely on GNSS-based timing, combining high accuracy with outstanding availability. Offering performance that far exceeds best-in-class magnetic cesium devices, the OSA 3300-HP is the industry’s first commercial high-performance optical cesium atomic clock. Featuring an all-digital design, it leverages optical-pumping techniques using laser diodes. This enables it to measure 100 times the number of atoms, making it radically more efficient compared to existing primary reference clock (PRC) technologies. Its product lifespan is 100% longer than competing high-performance magnetic cesium clocks; the OSA 3300-HP delivers optimum stability for over 10 years. What’s more, further to the launch of the OSA 3300-HP, ADVA is also announcing a dual-purpose enhancement of its OSA 3350 ePRC+. Now, as well as providing phase holdover as part of ePRTC systems, it can be utilized as a free-running frequency source with enhanced standard performance.
“What we’ve accomplished with our optical cesium atomic clock solutions is more than incremental innovation. Industrializing optical pumping techniques was widely considered to be impossible. But that’s what our team has achieved. Now, we’re taking precision timing to the next level, empowering networks with nanosecond accuracy and phenomenal stability,” commented Patrick Berthoud, time and frequency chief scientist at Oscilloquartz, ADVA. “As well as meeting new sync requirements, our OSA 3300-HP will help simplify operations with its easy-to-use GUI for intuitive configuration and operation. These devices will support advances in a host of different technology fields. Able to meet the most demanding applications in data centers, financial networks, smart grids, transportation, metrology, scientific research and more, they will also be a foundation for future innovation as we continue to expand the boundaries of possibility for accuracy and stability.”
Learn more about ADVA’s OSA 3300-HP in these slides: https://adva.li/osa-3300-hp-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005667/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
